112 related articles for article (PubMed ID: 38723388)
1. The effects of L-DOPA on gait abnormalities in a unilateral 6-OHDA rat model of Parkinson's disease.
Holden H; Venkatesh S; Budrow C; Nezaria S; Coyle M; Centner A; Lipari N; McManus G; Bishop C
Physiol Behav; 2024 Jul; 281():114563. PubMed ID: 38723388
[TBL] [Abstract][Full Text] [Related]
2. Striatal dopaminergic fiber recovery after acute L-DOPA treatment in 6-hydroxydopamine (6-OHDA) lesioned rats.
Fang C; Yin J; Xu Z; Wang Y; Xu H; Zhou H; Gao C
Cell Biochem Biophys; 2011 Jan; 59(1):49-56. PubMed ID: 20714825
[TBL] [Abstract][Full Text] [Related]
3. Effects of noradrenergic denervation by anti-DBH-saporin on behavioral responsivity to L-DOPA in the hemi-parkinsonian rat.
Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Bishop C
Behav Brain Res; 2014 Aug; 270():75-85. PubMed ID: 24837745
[TBL] [Abstract][Full Text] [Related]
4. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
[TBL] [Abstract][Full Text] [Related]
5. Effects of noradrenergic denervation on L-DOPA-induced dyskinesia and its treatment by α- and β-adrenergic receptor antagonists in hemiparkinsonian rats.
Barnum CJ; Bhide N; Lindenbach D; Surrena MA; Goldenberg AA; Tignor S; Klioueva A; Walters H; Bishop C
Pharmacol Biochem Behav; 2012 Jan; 100(3):607-15. PubMed ID: 21978941
[TBL] [Abstract][Full Text] [Related]
6. L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function.
Winkler C; Kirik D; Björklund A; Cenci MA
Neurobiol Dis; 2002 Jul; 10(2):165-86. PubMed ID: 12127155
[TBL] [Abstract][Full Text] [Related]
7. Automated gait analysis in bilateral parkinsonian rats and the role of L-DOPA therapy.
Westin JE; Janssen ML; Sager TN; Temel Y
Behav Brain Res; 2012 Jan; 226(2):519-28. PubMed ID: 22008381
[TBL] [Abstract][Full Text] [Related]
8. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats.
Cohen SR; Terry ML; Coyle M; Wheelis E; Centner A; Smith S; Glinski J; Lipari N; Budrow C; Manfredsson FP; Bishop C
Pharmacol Biochem Behav; 2022 Jun; 217():173393. PubMed ID: 35513119
[TBL] [Abstract][Full Text] [Related]
9. Exogenous corticosterone reduces L-DOPA-induced dyskinesia in the hemi-parkinsonian rat: role for interleukin-1beta.
Barnum CJ; Eskow KL; Dupre K; Blandino P; Deak T; Bishop C
Neuroscience; 2008 Sep; 156(1):30-41. PubMed ID: 18687386
[TBL] [Abstract][Full Text] [Related]
10. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
[TBL] [Abstract][Full Text] [Related]
11. The NK1 receptor antagonist N-acetyl-L-tryptophan reduces dyskinesia in a hemi-parkinsonian rodent model.
Thornton E; Hassall MM; Corrigan F; Vink R
Parkinsonism Relat Disord; 2014 May; 20(5):508-13. PubMed ID: 24637127
[TBL] [Abstract][Full Text] [Related]
12. Characterizing the relationship between L-DOPA-induced-dyskinesia and psychosis-like behaviors in a bilateral rat model of Parkinson's disease.
Lipari N; Centner A; Glinski J; Cohen S; Manfredsson FP; Bishop C
Neurobiol Dis; 2023 Jan; 176():105965. PubMed ID: 36526089
[TBL] [Abstract][Full Text] [Related]
13. Effects of pedunculopontine nucleus cholinergic lesion on gait and dyskinesia in hemiparkinsonian rats.
Chambers NE; Coyle M; Sergio J; Lanza K; Saito C; Topping B; Clark SD; Bishop C
Eur J Neurosci; 2021 Apr; 53(8):2835-2847. PubMed ID: 33426708
[TBL] [Abstract][Full Text] [Related]
14. RGS4 is involved in the generation of abnormal involuntary movements in the unilateral 6-OHDA-lesioned rat model of Parkinson's disease.
Ko WK; Martin-Negrier ML; Bezard E; Crossman AR; Ravenscroft P
Neurobiol Dis; 2014 Oct; 70():138-48. PubMed ID: 24969021
[TBL] [Abstract][Full Text] [Related]
15. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
[TBL] [Abstract][Full Text] [Related]
16. Implication of nigral dopaminergic lesion and repeated L-dopa exposure in neuropsychiatric symptoms of Parkinson's disease.
Loiodice S; Wing Young H; Rion B; Méot B; Montagne P; Denibaud AS; Viel R; Drieu La Rochelle C
Behav Brain Res; 2019 Mar; 360():120-127. PubMed ID: 30521934
[TBL] [Abstract][Full Text] [Related]
17. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
18. L-DOPA-induced dysregulation of extrastriatal dopamine and serotonin and affective symptoms in a bilateral rat model of Parkinson's disease.
Eskow Jaunarajs KL; George JA; Bishop C
Neuroscience; 2012 Aug; 218():243-56. PubMed ID: 22659568
[TBL] [Abstract][Full Text] [Related]
19. Globus pallidus, but not entopeduncular nucleus, 6-OHDA-induced lesion attenuates L-Dopa-induced dyskinesia in the rat model of Parkinson's disease.
Marin C; Bonastre M; Fuentes M; Mullol J
Pharmacol Biochem Behav; 2020 Oct; 197():173013. PubMed ID: 32758524
[TBL] [Abstract][Full Text] [Related]
20. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
